Key events, in time order
CEO increases stake after 30% dip in 3 months, signaling insider conviction
PET imaging in third patient shows neuroinflammation reduction, adding detail to ongoing trial updates
None yet
None yet
A trader is shifting capital from $TSLL to $TLSA leaps, citing better covered call premiums as the catalyst for this move.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
A biotech developing antibody and small-molecule drugs for autoimmune diseases and cancer, with lead candidate Foralumab targeting Crohn's, MS, and other conditions.
No revenue recorded; annual net losses of USD -0.02B in 2025 and 2023, with no gross margin—pure R&D burn with no commercial product yet.
No approved products or revenue, so no durable edge; competitors like AbbVie, Roche, and Bristol-Myers Squibb dominate the same autoimmune and oncology targets with deeper pipelines and resources.
